Cargando…
The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing
The only licensed vaccine against tuberculosis (TB), bacille Calmette–Guérin (BCG), protects against severe extrapulmonary forms of TB but is virtually ineffective against the most prevalent form of the disease, pulmonary TB. BCG was genetically modified at the Max Planck Institute for Infection Bio...
Autores principales: | Nieuwenhuizen, Natalie E., Kulkarni, Prasad S., Shaligram, Umesh, Cotton, Mark F., Rentsch, Cyrill A., Eisele, Bernd, Grode, Leander, Kaufmann, Stefan H. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610719/ https://www.ncbi.nlm.nih.gov/pubmed/28974949 http://dx.doi.org/10.3389/fimmu.2017.01147 |
Ejemplares similares
-
Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model
por: Figl, Julia, et al.
Publicado: (2023) -
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy
por: Rentsch, Cyrill A., et al.
Publicado: (2020) -
Next-Generation Vaccines Based on Bacille Calmette–Guérin
por: Nieuwenhuizen, Natalie E., et al.
Publicado: (2018) -
Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa
por: Loxton, André G., et al.
Publicado: (2017) -
Bacille Calmette-Guérin: An ophthalmic perspective
por: Jain, Manish, et al.
Publicado: (2022)